The approval covers all four strengths submitted by the company: 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. Shares of Biocon Ltd ended at ₹392.80, up by ₹4.55, or 1.17%, on the BSE today, December 5.
The approval covers all four strengths submitted by the company: 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. Shares of Biocon Ltd ended at ₹392.80, up by ₹4.55, or 1.17%, on the BSE today, December 5.